Matthew Harrison

After hinting at ongoing negotiations for larger vaccine deals on its earnings call, Moderna Inc (NASDAQ: MRNA) said late Tuesday that it signed an agreement with the U.S. government to supply 100 million doses of its coronavirus vaccine candidate mRNA-1273 for $1.525 billion. The Moderna...

Gilead Sciences, Inc. (NASDAQ: GILD) reported second-quarter revenues and earnings that trailed expectations. The Gilead Analysts Morgan Stanley analyst Matthew Harrison maintained an Equal-Weight rating and $79 price target for Gilead. Raymond James analyst Steven Seedhouse maintained a Market...

Although Biogen Inc (NASDAQ: BIIB) will face generic competitors for Tecfidera in the near term, the pricing in of aducanumab success may drive the stock to the mid-$300s, according to Morgan Stanley. The Biogen Analyst: Matthew Harrison upgraded Biogen from Underweight to Overweight and raised the...

Biogen Inc (NASDAQ: BIIB) is caught in more than one legal wrangle with generic companies over patents related to its key multiple sclerosis drug Tecfidera, which was approved by the FDA in March 2013. The Biogen Analyst: Morgan Stanley analyst Matthew Harrison has an Underweight rating on...

Moderna Inc (NASDAQ: MRNA) shares were bulldozing their way toward record highs Wednesday in reaction to the publication in the New England Journal of Medicine of detailed interim Phase 1 data for mRNA-1273, its SARS-CoV2 vaccine candidate. The Moderna Analysts: BofA Securities analyst...

Morgan Stanley, which recently named Moderna Inc (NASDAQ: MRNA) as one of the likeliest candidates to succeed in the coronavirus vaccine race, reviewed the interim Phase 1 data released by the company Monday. The Moderna Analyst Matthew Harrison maintained an Overweight rating on Moderna...

With about eight coronavirus vaccine candidates in clinical trials and 110 more in clinical testing, the race to a commercial product is intensifying. Against this backdrop, an analyst at Morgan Stanley looked at the most promising programs.  Millions of doses of the vaccine could be...

Gilead Sciences, Inc. (NASDAQ: GILD) reported an earnings and sales beat Thursday, but apprehension surrounding the drugmaker's remdesivir, under evaluation as a potential COVID-19 treatment, are weighing down on the stock. The Gilead Analysts Wells Fargo Securities analyst Jim...

Gilead Sciences, Inc. (NASDAQ: GILD) surged more than 16% after hours Thursday when STAT News reported promising preliminary results for a prospective COVID-19 therapy. In a trial conducted by the University of Chicago Medicine, remdesivir has been associated with rapid recovery and near-term...

Sarepta Therapeutics Inc (NASDAQ: SRPT) has entered a partnership with Roche (OTC: RHHBY) to commercialize SRP-9001, its gene therapy for Duchenne Muscular Dystrophy, outside of the U.S. The deal secures Sarepta a $1.15 billion upfront payment — $750 million in cash and $400 million in an...

Biotech investing is risk-fraught, but for investors who make the right bets, the returns can be staggering. As the year draws to a close, Morgan Stanley said stock selection is the key to biotech investing in 2020 as drug pricing and election fears wane, offering incremental upside for...

Sage Therapeutics Inc (NASDAQ: SAGE) shares fell more than 60% Thursday following a negative readout for its lead asset in major depressive disorder. The Analysts Morgan Stanley analyst Matthew Harrison maintained an Overweight rating for Sage but lowered the price target from $217 to $125. (See...

Gilead Sciences, Inc. (NASDAQ: GILD) reported after the market close Thursday with results that left investors uninspired.  The Analysts Morgan Stanley analyst Matthew Harrison maintained an Equal-weight rating on Gilead with a $75 price target. Baird analyst Brian Skorney maintained...

Biogen Inc (NASDAQ: BIIB) shares rallied strongly Tuesday after the biotech said it plans a regulatory filing for its Alzheimer's drug aducanumab, which the company had written off back in March. The Analysts Morgan Stanley analyst Matthew Harrison maintained an Underweight rating on...

Biogen Inc (NASDAQ: BIIB) shares plunged nearly 30 percent Thursday after, along with development partner Eisai Co., Ltd (OTC: ESALY) announced the decision to scrap two late-stage trials evaluating their Alzheimer's candidate aducanumab. The Analysts Mizuho Securities analyst Salim Syed...